← All trials
NCT05667129
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Dec 28, 2022
- Last posted
- Dec 28, 2022
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xeno BiosciencesLead sponsor
- CRU Hungary Early Phase UnitOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.